Prostatitis, or benign hypertrophy of the prostate gland (BHP), is a common disease in males. The incidence rate increases with age, starting at the age of approximately fifty.

Enlargement, oedema and inflammatory changes result in worsened urine flow, causing more frequent urination in small volumes. It is a progressive disease which can end in failure of the lower urinary tract function and kidney insufficiency.

Prostatitis is rather annoying but can also lead to the serious risk of developing malignant prostatic disease. Upon enlargement, the prostate gland suppresses the bottom of the urinary bladder and reflective spasm occurs in the smooth muscle of the urinary bladder neck, prostate, and part of the urethra, resulting in an anatomic obstruction.

A prostate enlarged due to benign hyperplasia leads to urinary disorders – showing as symptoms of the lower urinary tract on the basis of prostate benign hyperplasia; clinically, this will show up as a defecation or micturition disorder, urinary retention, urinary tract infection, hematuria or hydronephrosis and renal insufficiency. Prostatitis is treated in a pharmacology manner – most frequently inhibitors are administered – 5alpha-reductases, alphablocks, physiotherapeutics – or by surgery.

Read the results of the following clinical studies that demonstrate the success rate of low-frequency pulsed magnetic therapy in treatment of this condition.

Clinical studies by diagnosis:

Related diagnosis: Prostatitis, BHP